Roche has decided to exercise its option to use Norak Biosciences technology for a second year as part of a potential drug compound screening process, Norak said Wednesday.
Roche is utilizing Norak’s Transfluor process.
The original agreement was signed in September of 2002.
Financial terms weren’t disclosed.
Norak: www.norakbio.com
